Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
|
|
P3 Health Partners Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/07/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Interactive Data |
| 03/31/2023 |
8-K
| Quarterly results |
| 01/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/11/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I...|
Docs:
|
"P3 Health Partners Reaffirms Guidance For 2022 and Announces Guidance For 2023 Henderson, Nev., January 11, 2023 -- P3 Health Partners Inc . , a patient-centered and physician-led population health management company, is participating in J.P. Morgan’ s 41st Annual Healthcare Conference, being held in San Francisco, CA from January 9-12, 2023. In advance of the associated presentation, P3 is reaffirming full-year 2022 financial guidance and announcing financial guidance for the full-year 2023. · For the full-year 2022, P3 is reaffirming the revenue guidance range given on the third quarter earnings call of between $1.025 billion and $1.075 billion, representing a 61% to 69% increase over 2021. · The at-risk Medicare Advantage membership is still expected to be greater than 100..." |
|
| 12/21/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 12/13/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/01/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/27/2022 |
8-K
| Quarterly results |
| 10/20/2022 |
8-K
| Quarterly results |
| 10/19/2022 |
8-K
| Quarterly results |
| 10/04/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 08/19/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 05/24/2022 |
8-K
| Quarterly results |
| 05/18/2022 |
8-K
| Quarterly results |
| 04/25/2022 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Other Events ... |
| 04/14/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/09/2022 |
8-K
| Quarterly results |
| 01/12/2022 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 12/23/2021 |
8-K
| Quarterly results |
| 12/09/2021 |
8-K
| Quarterly results |
| 12/03/2021 |
8-K
| Quarterly results |
| 12/01/2021 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 11/22/2021 |
8-K
| Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial Stat... |
| 09/22/2021 |
8-K
| Quarterly results |
| 06/01/2021 |
8-K
| Quarterly results |
| 06/01/2021 |
8-K
| Quarterly results |
| 05/25/2021 |
8-K
| Quarterly results |
| 05/24/2021 |
8-K
| Quarterly results |
| 02/19/2021 |
8-K
| Other Events, Financial Statements and Exhibits |
| 02/16/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : February 9, 2021 Foresight Acquisition Corp. Delaware 001-40033 85-2992794 233 N. Michigan Avenue Chicago, IL 60601 882-8897 Not Applicable Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the...",
"Underwriting Agreement, between the Company and Cowen and Company, LLC",
"Business Combination Marketing Agreement, among the Company, Cowen and Company, LLC and William Blair & Company, L.L.C",
"Amended and Restated Certificate of Incorporation of the Company",
"Warrant Agreement, between the Company and Continental Stock Transfer & Trust Company",
"Letter Agreement, among the Company, Foresight Sponsor Group, LLC, FA Co-Investment LLC and each of the executive officers and directors of the Company",
"Investment Management Trust Agreement, between the Company and Continental Stock Transfer & Trust Company",
"Registration Rights Agreement, among the Company, Foresight Sponsor Group, LLC and certain securityholders",
"Unit Subscription Agreement, between the Company and Foresight Sponsor Group, LLC",
"Unit Subscription Agreement, between the Company and FA CO-Investment, LLC",
"Foresight Acquisition Corp. Announces Pricing of $275,000,000 Initial Public Offering Foresight Acquisition Corp. , a blank check company targeting a technology-enabled consumer or consumer healthcare business, announced today the pricing of its initial public offering of 27,500,000 units at $10.00 per unit. Each unit consists of one share of Class A common stock and one-third of one redeemable warrant. Each whole warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company's units are expected to be listed on the Nasdaq Capital Market and ..." |
|
|
|